On May 25, 2026, TheMarker reported that the tender to sell the Wolt Market business had passed its initial stage, with contenders submitting preliminary bids. A group that included Good Pharm's founders (Ohad Sandler and Adam Fridler) together with Mor Investment House and Menora Mivtachim Pension submitted a bid; Migdal (which holds stakes in Israel Post and Pango) also expressed interest, alongside the Apax investment fund and other parties. By contrast, Victory, Leumi Partners, and Delek Israel — which had shown initial interest — did not advance to the next stage. According to TheMarker, Wolt Market is a loss-making business, and the tender also includes a growth-strategy proposal component, not price alone. On May 26, ice.co.il similarly reported Victory's withdrawal from the race, and Calcalist reported that Wolt Market expects an additional operating loss of about NIS 100 million over the next three years. The tender reached its decision stage by late July: on July 26, Ynet, Calcalist, and ice.co.il reported that four groups had submitted bids, with the highest bid at around NIS 300 million. According to Ynet, Paz and Good Pharm's founders are the two leading contenders — the only players with retail infrastructure capable of channeling significant activity into Wolt Market in the short term. A final decision on the buyer's identity is expected in the coming weeks, with industry observers estimating that price alone will not be decisive — Competition Authority approval will also be required.
The Race to Sell Wolt Market: How Paz and Good Pharm Were Left Alone in the Arena

The tender to sell Wolt's retail delivery unit, Wolt Market, passed an initial screening stage in May 2026 in which several of the economy's largest companies withdrew. By July 2026, Paz and Good Pharm's founders remained as the two leading contenders, with the highest bid reaching around NIS 300 million.
Why it matters
A deal worth hundreds of millions of shekels for a loss-making business (Wolt Market) exposes the difficulty Wolt faces in making its retail arm profitable, and also demonstrates that Israel's retail-delivery market is converging on two players with suitable physical infrastructure (Paz, Good Pharm) as the only realistic candidates.
What's next
Competition Authority approval could delay or alter the deal's terms. If Paz wins, a significant shift in its retail strategy is possible; if Good Pharm's founders win, integration with their existing supermarket chain will likely be a central focus.
Verified facts
- The Wolt Market sale tender passed an initial screening stage by 25.05.2026, with bids from a Good Pharm founders + Mor Investment House/Pension group, and additional interest from Migdal and Apax (TheMarker)
- Victory, Leumi Partners, and Delek Israel withdrew from the race despite initial interest (TheMarker, ice.co.il, 25-26.05.2026)
- Wolt Market expects an additional operating loss of about NIS 100 million over the next three years (Calcalist, 26.05.2026)
- By 26.07.2026, 4 groups had submitted final bids, up to about NIS 300 million (Ynet, Calcalist, ice.co.il)
- Paz and Good Pharm's founders are the two leading contenders, as holders of relevant retail infrastructure (Ynet)